Reata Reports Results of Omaveloxolone in P-II MOXIe Registrational Study for Patients with Friedreich’s Ataxia

 Reata Reports Results of Omaveloxolone in P-II MOXIe Registrational Study for Patients with Friedreich’s Ataxia

Reata Regains Exclusive Worldwide Rights of its Nrf2 Activator Product Platform from AbbVie

Shots:

  • The registrational part 2 of the P-II MOXIe study involves assessing of Omaveloxolone (150mg) vs PBO in 103 patients in a ratio (1:1) with FA at 11 sites across United States, Europe, and Australia for 48wks.
  • The P-II MOXIe study results: met its 1EPs i.e, @48wks., 2.40point improvement in mFARS; mean improvement in mFARS from baseline (-1.55 points vs +0.85 points); 1.93point improvement in mFARS in patients with pes cavus
  • Omaveloxolone (PO, qd) is an investigational oral Nrf2 activator, promoting restoration of mitochondrial function, reduction of oxidative stress and inhibition of pro-inflammatory signaling and has received the US FDA & EMA’s ODD for FA

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post